{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T05:37:18Z","timestamp":1697348238052},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,4,21]],"date-time":"2010-04-21T00:00:00Z","timestamp":1271808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s10147-010-0079-0","type":"journal-article","created":{"date-parts":[[2010,4,19]],"date-time":"2010-04-19T21:12:04Z","timestamp":1271711524000},"page":"433-439","source":"Crossref","is-referenced-by-count":2,"title":["The negative-balance isolated pelvic perfusion method using ultrahigh-dose cisplatin for invasive bladder cancer with poor risk"],"prefix":"10.1007","volume":"15","author":[{"given":"Ryoji","family":"Kimata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Kumazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,21]]},"reference":[{"key":"79_CR1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0302-2838(03)00150-7","volume":"44","author":"M Kuczyk","year":"2003","unstructured":"Kuczyk M, Turkeri L, Hammerer P et al (2003) Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol 44:57\u201364","journal-title":"Eur Urol"},{"key":"79_CR2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s10147-004-0434-0","volume":"9","author":"Y Sumiyoshi","year":"2004","unstructured":"Sumiyoshi Y (2004) Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives. Int J Clin Oncol 9:484\u2013490","journal-title":"Int J Clin Oncol"},{"key":"79_CR3","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.2006.07.6729","volume":"24","author":"C Rodel","year":"2006","unstructured":"Rodel C, Weiss C, Sauer R (2006) Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24:5536\u20135544","journal-title":"J Clin Oncol"},{"key":"79_CR4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1442-2042.2008.02032.x","volume":"15","author":"K Hashine","year":"2008","unstructured":"Hashine K, Miura N, Numata K et al (2008) Health-related quality of life after bladder preservation therapy for muscle invasive bladder cancer. Int J Urol 15:403\u2013406","journal-title":"Int J Urol"},{"key":"79_CR5","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1097\/01.ju.0000176455.82079.33","volume":"174","author":"T Yoneda","year":"2005","unstructured":"Yoneda T, Adachi H, Urakami S et al (2005) Health related quality of life after orthotopic neobladder construction and its comparison with normative values in the Japanese population. J Urol 174:1944\u20131947","journal-title":"J Urol"},{"key":"79_CR6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1272\/jnms.71.263","volume":"71","author":"H Shimizu","year":"2004","unstructured":"Shimizu H, Nishimura T, Kimura G et al (2004) Effect of adjuvant transarterial infusion of anticancer agents after transurethral resection in patients with pT2a muscle invasive transitional cell carcinoma of the bladder: five and ten-year outcome. J Nippon Med Sch 71:263\u2013269","journal-title":"J Nippon Med Sch"},{"key":"79_CR7","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/jjco\/hym129","volume":"37","author":"N Miyanaga","year":"2007","unstructured":"Miyanaga N, Akaza H, Hinotsu S et al (2007) Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy. Jpn J Clin Oncol 37:852\u2013857","journal-title":"Jpn J Clin Oncol"},{"key":"79_CR8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/jjco\/hyp023","volume":"39","author":"K Hashine","year":"2009","unstructured":"Hashine K, Kusuhara Y, Miura N et al (2009) Bladder preservation therapy conducted by intra-arterial chemotherapy and radiotherapy for muscle invasive bladder cancer. Jpn J Clin Oncol 39:381\u2013386","journal-title":"Jpn J Clin Oncol"},{"key":"79_CR9","first-page":"917","volume":"43","author":"DJ Stewart","year":"1983","unstructured":"Stewart DJ, Benjamin RS, Zimmerman S et al (1983) Clinical pharmacology of intraarterial cis-diamminedichoroplatinum (II). Cancer Res 43:917\u2013920","journal-title":"Cancer Res"},{"key":"79_CR10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ygyno.2004.08.027","volume":"95","author":"S Motoyama","year":"2004","unstructured":"Motoyama S, Hamana S, Ku Y et al (2004) Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa\u2013IVa cervical cancer. Gynecol Oncol 95:576\u2013582","journal-title":"Gynecol Oncol"},{"key":"79_CR11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1056\/NEJM195911192612101","volume":"261","author":"WG Austen","year":"1959","unstructured":"Austen WG, Monaco AP, Richardson GS et al (1959) Treatment of malignant pelvic tumor by extracorporeal perfusion with chemotherapeutic agents. N Engl J Med 261:1037\u20131045","journal-title":"N Engl J Med"},{"key":"79_CR12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00432-004-0666-4","volume":"131","author":"S Murata","year":"2005","unstructured":"Murata S, Tajima H, Kusakai G et al (2005) Reduction of drug leakage by negative-balance isolated pelvic perfusion: correlation between leakage and in-out flow rate in a pig model. J Cancer Res Clin Oncol 131:575\u2013580","journal-title":"J Cancer Res Clin Oncol"},{"key":"79_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/COC.0b013e318136e27a","volume":"31","author":"H Azuma","year":"2008","unstructured":"Azuma H, Kotake Y, Yamamoto K et al (2008) Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer. Am J Clin Oncol 31:11\u201321","journal-title":"Am J Clin Oncol"},{"key":"79_CR14","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"CN Sternberg","year":"2001","unstructured":"Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol 19:2638\u20132646","journal-title":"J Clin Oncol"},{"key":"79_CR15","volume-title":"Cancer chemotherapy, challenges for the future","author":"JM Collins","year":"1989","unstructured":"Collins JM (1989) Pharmacokinetic rationale for intraarterial therapy. In: Kimura K (ed) Cancer chemotherapy, challenges for the future, vol 4. Excerpta Medica, Amsterdam"},{"key":"79_CR16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s002800050548","volume":"39","author":"N Nagai","year":"1996","unstructured":"Nagai N, Kinoshita M, Ogata H et al (1996) Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 39:131\u2013137","journal-title":"Cancer Chemother Pharmacol"},{"key":"79_CR17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00432-007-0217-x","volume":"133","author":"K Nakazato","year":"2007","unstructured":"Nakazato K, Kim C, Terajima K et al (2007) Large volume loading to prevent cisplatin-induced nephrotoxicity during negative-balance isolated pelvic perfusion. J Cancer Res Clin Oncol 133:741\u2013747","journal-title":"J Cancer Res Clin Oncol"},{"key":"79_CR18","first-page":"1107","volume":"15","author":"JW Harold","year":"2007","unstructured":"Harold JW, Michael D, Giovanni B et al (2007) Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. Ann Surg Oncol 15:1107\u20131116","journal-title":"Ann Surg Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-010-0079-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-010-0079-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-010-0079-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T16:23:28Z","timestamp":1559147008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-010-0079-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,21]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["79"],"URL":"https:\/\/doi.org\/10.1007\/s10147-010-0079-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,21]]}}}